The Drug Enforcement Administration walked into its own administrative law judge hearing on June 29 and announced, without hesitation, that it supports the proposed rule to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. That's not a small thing. For an agency historically associated with enforcement of drug prohibition, openly backing the most significant federal drug classification shift in more than 50 years carries real weight - for operators, investors, compliance teams, and every licensed cannabis business watching from the sidelines.
The hearing, held at DEA headquarters in Arlington, Va., is scheduled to run through July 15. It features seven anti-rescheduling parties selected by the DEA to participate - a lineup that drew scrutiny from pro-rescheduling advocates who wondered whether the government was deliberately stacking the deck against itself. State-level operators from medical and adult-use markets alike have been tracking these proceedings closely, understanding that a Schedule III designation would reshape federal tax treatment, banking access, and research pathways almost overnight. Dispensary technology providers, including platforms like IndicaOnline in Rhode Island, have similarly been monitoring federal rescheduling developments, since any shift in cannabis's controlled substance status could alter compliance infrastructure requirements for point-of-sale systems and seed-to-sale tracking across regulated markets.
DEA attorney James J. Schwartz opened Monday's proceedings by making three things explicit: the government is the proponent of the proposed rule, it supports that rule, and the hearing's singular purpose is to establish whether cannabis has currently accepted medical use - known in regulatory shorthand as CAMU. "That decision has already been made," Schwartz said, referring to the DOJ Office of Legal Counsel's 2024 opinion that the HHS's two-part test for determining CAMU was legally sufficient. Anti-rescheduling parties cannot relitigate that methodology before the ALJ, he said, because the OLC opinion is binding on the DEA and the tribunal itself.
What CAMU Actually Means - and Why It's the Whole Ballgame
Under the Controlled Substances Act, a drug cannot remain on Schedule I if it has currently accepted medical use. That's the legal logic driving this entire proceeding. The government's burden isn't to prove cannabis is safe in an absolute sense - it's to demonstrate that at least one CAMU exists. If it clears that bar, cannabis can no longer legally occupy Schedule I, full stop.
The HHS made its CAMU determination in August 2023, identifying three conditions for which cannabis has accepted medical use: anorexia related to a medical condition, chemotherapy-induced nausea and vomiting, and pain. That finding was built on an eight-factor analysis conducted over ten months, drawing on national surveys, literature reviews from both the FDA's internal medical team and the University of Florida's epidemiology group, state-level data from Minnesota and Maryland, and the FDA-approved cannabis-derived drugs Marinol and Syndros - both of which contain dronabinol, a synthesized form of THC approved for nausea and vomiting associated with chemotherapy.
Dominic Chiapperino, Ph.D., director of controlled substance staff for the FDA's Center for Drug Evaluation and Research and the government's first witness, testified that 39 clinical trials were available to assess cannabis as a pain treatment - the condition with the most supporting evidence. "The studies were more supportive of therapeutic benefit for patients with neuropathic pain," he said. The FDA also compared cannabis's relative abuse potential and dependence liability to substances across multiple schedules, including heroin, fentanyl, cocaine, ketamine, benzodiazepines, and alcohol - the last of which is not a controlled substance at all, a comparison that carries its own implicit regulatory commentary.
The Two-Part Test and the Fight Over Methodology
Here's where things get technically contentious. The DEA historically used a five-part test to determine CAMU - a framework it developed following a 1992 court challenge. One of those five factors asks whether a drug's chemistry is known and reproducible. For botanical cannabis, a plant whose chemical composition varies by strain, cultivation method, and processing, that standard creates a significant obstacle. Anti-rescheduling parties have argued it's effectively an impassable one.
HHS bypassed that standard entirely when it developed its two-part test: Are licensed health care practitioners recommending cannabis to patients under state regulation, and is there credible scientific evidence supporting a therapeutic effect for at least one condition? The OLC signed off on that methodology in 2024. And Schwartz made plain that the ALJ - Derek C. Julius, newly appointed to oversee the hearing - cannot entertain challenges to the two-part test. That door is closed.
That didn't stop David Evans, an attorney for the National Drug & Alcohol Screening Association, from trying to raise it during cross-examination of Chiapperino. He asked why HHS and DEA had abandoned the five-part test. The DEA's legal team objected. Evans withdrew the question. His allotted one hour of cross-examination stretched to two hours, largely because DEA counsel objected repeatedly to questions deemed speculative or outside the scope of Chiapperino's Touhy letter - the FDA authorization that limited his testimony to three specific topics: the FDA's eight-factor analysis, its CAMU conclusions, and the Schedule III recommendation. Nothing else was on the table.
What This Means for Licensed Cannabis Businesses
A Schedule III designation would not legalize cannabis federally. That distinction matters and operators would do well not to conflate the two. Schwartz said so directly: the hearing is not about recreational use, and it is not about legalization. What rescheduling would do is remove cannabis from the most restrictive federal classification - one that currently bars licensed operators from deducting ordinary business expenses under IRS tax code Section 280E, limits federally insured banks from providing standard financial services, and blocks most clinical research pathways.
For multi-state operators carrying significant 280E tax burdens, the relief from Schedule III reclassification would be immediate and material. For cannabis brands and wholesalers trying to access institutional capital or traditional banking relationships, rescheduling represents a structural shift in the risk calculus that lenders and payment processors apply. For compliance-focused operators in medical markets - the ones whose regulatory frameworks most closely resemble the CAMU conditions HHS identified - the practical implications of rescheduling could arrive sooner than many expect.
Regulatory attorney Gary Kaminsky, one of roughly 25 members of the public who attended the June 29 hearing, put it plainly: "I don't know if that's revelatory to us all, but it makes you realize that this is a very substantive hearing." A DEA-led proceeding where the agency's own attorney opens by declaring support for loosening federal cannabis restrictions is not business as usual. The ALJ hearing runs through July 15. The industry should be paying attention.
